FindTrial
Sign In

PROSTVAC-V

BIOLOGICAL3 trials

Sponsors

Bavarian Nordic, National Cancer Institute (NCI), Washington University School of Medicine

Conditions

Metastatic Hormone-Sensitive Prostate CancerNeoplasms, ProstaticProstate CancerProstate Cancer MetastaticProstate Neoplasms

Phase 1

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
CompletedNCT03532217
Washington University School of MedicineMetastatic Hormone-Sensitive Prostate Cancer
Start: 2018-09-14End: 2022-07-25Updated: 2022-08-05

Phase 2

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
CompletedNCT02649855
National Cancer Institute (NCI)Neoplasms, Prostatic, Prostate Cancer, Prostate Neoplasms
Start: 2016-01-19End: 2023-12-05Updated: 2024-08-06

Phase 3

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
CompletedNCT01322490
Bavarian NordicProstate Cancer Metastatic
Start: 2011-11-28End: 2017-12-15Updated: 2019-09-04

Related Papers

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer.
Journal of Clinical Oncology2023-02-20
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology2022-06-018 citations
PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).
Journal of Clinical Oncology2022-06-011 citations
Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.
Journal of Clinical Oncology2022-02-163 citations
Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC).
Journal of Clinical Oncology2021-05-201 citations
A pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC).
Journal of Clinical Oncology2021-02-205 citations
Clinical efficacy of abiraterone and enzalutamide metastatic castration sensitive prostate cancer patients who progressed rapidly on docetaxel with a genomic analysis.
Journal of Clinical Oncology2019-05-20
Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.
Journal of Clinical Oncology2019-03-013 citations
Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.
Journal of Clinical Oncology2018-05-2016 citations
Prospect: A randomized double-blind phase 3 efficacy study of PROSTVAC-VF immunotherapy in men with asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer.
Journal of Clinical Oncology2015-05-2017 citations
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy.
2014-10-1415 citations
Immune impact induced by PSA-tricom, a therapeutic vaccine for prostate cancer.
Journal of Clinical Oncology2014-02-01
Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy
Journal for ImmunoTherapy of Cancer2014-01-012 citations